Idazoxan is a (REPEAT)
**Core Concept**
Idazoxan is a non-selective α2-adrenergic receptor antagonist. It primarily acts by blocking the presynaptic α2-adrenergic receptors in the central nervous system, thereby increasing the release of norepinephrine.
**Why the Correct Answer is Right**
Idazoxan increases the release of norepinephrine by blocking the negative feedback mechanism mediated by α2-adrenergic receptors. Normally, when norepinephrine is released, it binds to α2-adrenergic receptors, which in turn inhibit the release of further norepinephrine. By blocking these receptors, idazoxan prevents this negative feedback, leading to an increase in norepinephrine release. This action is primarily observed in the central nervous system, particularly in the locus coeruleus.
**Why Each Wrong Option is Incorrect**
**Option A:** This is incorrect because idazoxan is not primarily a dopamine receptor antagonist. While it may have some effects on dopamine receptors, its primary mechanism of action is as an α2-adrenergic receptor antagonist.
**Option B:** This is incorrect because idazoxan is not a selective α2-adrenergic receptor agonist. Its primary action is to block α2-adrenergic receptors, rather than activating them.
**Option C:** This is incorrect because idazoxan is not a non-selective adrenergic receptor agonist. It specifically blocks α2-adrenergic receptors, rather than activating multiple adrenergic receptors.
**Clinical Pearl / High-Yield Fact**
Idazoxan has been investigated as a potential treatment for depression, as its ability to increase norepinephrine release may help to improve mood. However, its use in humans is still experimental and requires further study.
**Correct Answer:** D. Non-selective α2-adrenergic receptor antagonist